About Us
Our Company
Leadership
Contact
Medical Education Grants
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline LTX-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Menu
About Us
Our Company
Leadership
Contact
Medical Education Grants
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline LTX-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Press Releases
Press Releases
Year
2018
2019
2020
2021
Submit
December 15, 2021
Verrica Pharmaceuticals Announces Acceptance by FDA of NDA Resubmission for VP-102 for the Treatment of Molluscum Contagiosum
November 29, 2021
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
November 18, 2021
Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
November 12, 2021
Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results
September 20, 2021
Verrica Pharmaceuticals Receives Complete Response Letter from the FDA identifying deficiencies at a facility of a Contract Manufacturer for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
1
2
3
4
5
next >
